On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer on September 18, 2018 at 4:56 am
About BioTime, Inc. BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are ... a wide variety of cells and tissue types including brain, bone, sk... […]
- The No. 1 knee disease on September 13, 2018 at 6:55 pm
Being mundane, they too, are subjected to disorder, disease and ageing. Osteoarthritis, the progressive degeneration of the knee due to ... muscle weakness, decreased bone density, knee joint instabil... […]
- Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration on September 13, 2018 at 10:09 am
13, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences, (SWX:KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration, announced today that it ... […]
- Scientists Are Developing New Ways to Treat Disease With Cells, Not Drugs on September 13, 2018 at 3:33 am
When Obar was pregnant with their first child, Gabriel, the couple was told that if he had the disease, his prognosis ... are extracted from a donor’s bone marrow, processed in a lab and ... […]
- Bone Degeneration Therapeutics Market to Garner Brimming Revenues by 2024 on September 11, 2018 at 5:04 pm
Aging is one of the natural causes of bone degeneration but is also accelerated by several conditions such as injuries, congenital disorders, diabetes and obesity. Numbness or tingling feeling in case ... […]
- Biodegradable Bone Graft Polymers Market 2018 Key Players KLS Martin Group, Fo, Evonik, Polysciences, Inc. on September 11, 2018 at 3:24 am
Biodegradable Bone Graft Polymers Market size will exceed USD 690 ... growing application for biodegradable polymers particularly because of rise in degenerative disc diseases. Poly lactic acid copoly... […]
- Bone Graft Substitute Market 2018 Major Drivers | by type autograft, demineralized bone matrix, synthetic bone grafts & more – Finds MRFR on September 10, 2018 at 5:56 am
The procedure for bone grafting comprises transplantation of the bone tissue to regenerate and augment bones which are lost due to injury or disease. With the emerging ... The growing geriatric is mor... […]
- Managing lower back pain disorders on September 7, 2018 at 1:53 am
Back pain is a symptom, not a disease, with a range of triggers including; mechanical causes, degenerative and inflammatory conditions ... and a neural arch that encircles the spinal cord in a ring of ... […]
- IUPUI professor lands NIH grant to research methods to strengthen bones, resist fractures on September 5, 2018 at 10:38 am
INDIANAPOLIS -- There may be a new way to treat degenerative bone conditions ... of approaching the treatment of fragility-related diseases," Wallace said. "From osteoporosis to diabetes' effects on b... […]
via Bing News